Franklin Street Advisors Inc. NC Has $45.71 Million Stock Holdings in AbbVie Inc. $ABBV

Franklin Street Advisors Inc. NC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 1.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 181,638 shares of the company’s stock after buying an additional 2,421 shares during the quarter. AbbVie makes up 2.6% of Franklin Street Advisors Inc. NC’s holdings, making the stock its 9th biggest holding. Franklin Street Advisors Inc. NC’s holdings in AbbVie were worth $45,707,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Tenzing Financial LLC bought a new position in shares of AbbVie in the second quarter worth about $227,000. Veery Capital LLC acquired a new stake in shares of AbbVie in the 2nd quarter valued at approximately $224,000. Shira Ridge Wealth Management bought a new stake in shares of AbbVie during the 2nd quarter valued at approximately $222,000. World Equity Group Inc. grew its holdings in shares of AbbVie by 1.2% during the 2nd quarter. World Equity Group Inc. now owns 7,975 shares of the company’s stock valued at $2,007,000 after purchasing an additional 96 shares during the last quarter. Finally, Professional Financial Advisors LLC increased its position in AbbVie by 5.7% during the 2nd quarter. Professional Financial Advisors LLC now owns 1,904 shares of the company’s stock worth $479,000 after purchasing an additional 103 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several research reports. Bank of America increased their price objective on shares of AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Barclays upped their price target on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. UBS Group increased their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Royal Bank Of Canada boosted their price objective on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Finally, HSBC reaffirmed a “buy” rating and issued a $300.00 target price on shares of AbbVie in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $275.70.

AbbVie Price Performance

ABBV opened at $245.82 on Monday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The company’s 50 day moving average price is $241.96 and its two-hundred day moving average price is $225.04. The firm has a market capitalization of $434.31 billion, a price-to-earnings ratio of 69.44, a PEG ratio of 0.82 and a beta of 0.30.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.